Analysts expect that Foundation Medicine Inc (NASDAQ:FMI) will announce earnings of ($1.00) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Foundation Medicine’s earnings. The lowest EPS estimate is ($1.15) and the highest is ($0.86). Foundation Medicine reported earnings per share of ($1.02) during the same quarter last year, which indicates a positive year over year growth rate of 2%. The company is expected to report its next quarterly earnings results on Wednesday, February 28th.

According to Zacks, analysts expect that Foundation Medicine will report full-year earnings of ($4.44) per share for the current year, with EPS estimates ranging from ($4.60) to ($4.31). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.81) per share, with EPS estimates ranging from ($4.30) to ($3.13). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Foundation Medicine.

Foundation Medicine (NASDAQ:FMI) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.90) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.06) by $0.16. The firm had revenue of $42.66 million for the quarter, compared to the consensus estimate of $37.99 million. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. The company’s revenue was up 45.0% on a year-over-year basis. During the same period last year, the firm earned ($0.90) EPS.

Several analysts have recently commented on FMI shares. BidaskClub upgraded shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Zacks Investment Research upgraded shares of Foundation Medicine from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a report on Monday, November 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Foundation Medicine currently has a consensus rating of “Hold” and an average price target of $45.33.

Shares of Foundation Medicine (FMI) opened at $67.10 on Monday. The company has a market cap of $2,432.55, a price-to-earnings ratio of -15.01 and a beta of -0.01. Foundation Medicine has a 52-week low of $17.50 and a 52-week high of $74.30. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.03 and a current ratio of 2.24.

In other Foundation Medicine news, SVP Robert W. Hesslein sold 1,864 shares of Foundation Medicine stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $64.00, for a total value of $119,296.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Evan/ Fa Jones sold 6,500 shares of Foundation Medicine stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $60.66, for a total transaction of $394,290.00. Following the completion of the transaction, the director now directly owns 19,652 shares of the company’s stock, valued at $1,192,090.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,837 shares of company stock worth $4,289,412. 2.70% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of FMI. Chevy Chase Trust Holdings Inc. boosted its position in Foundation Medicine by 1.1% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 1,059,141 shares of the company’s stock valued at $42,572,000 after buying an additional 11,934 shares during the period. Discovery Group I LLC boosted its position in Foundation Medicine by 0.9% in the 3rd quarter. Discovery Group I LLC now owns 836,986 shares of the company’s stock valued at $33,647,000 after buying an additional 7,181 shares during the period. Oppenheimer & Co. Inc. boosted its position in Foundation Medicine by 5.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 723,480 shares of the company’s stock valued at $29,084,000 after buying an additional 39,390 shares during the period. Vanguard Group Inc. boosted its position in Foundation Medicine by 8.2% in the 2nd quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock valued at $25,096,000 after buying an additional 47,843 shares during the period. Finally, Lord Abbett & CO. LLC boosted its position in Foundation Medicine by 146.0% in the 2nd quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock valued at $23,024,000 after buying an additional 343,770 shares during the period. 32.68% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/15/1-00-earnings-per-share-expected-for-foundation-medicine-inc-fmi-this-quarter.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Get a free copy of the Zacks research report on Foundation Medicine (FMI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.